EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Protective low-avidity anti-tumour CD8+ T cells are selectively attenuated by regulatory T cells

Gessa Sugiyarto, David Prossor, Osman Dadas, E David Arcia-Anaya, Tim Elliott, Edward James iD

Immunotherapy Advances · 2021

DOI: 10.1093/immadv/ltaa001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunotherapy Advances, 2021. Verfasst von Gessa Sugiyarto und 5 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Cancer Immunology, School of Cancer Sciences, University of Southampton Faculty of Medicine, University Hospital Southampton, Southampton,…. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Cancer Research UK, Norman Godinho Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Regulatory T cells (Treg) play a major role in the suppression of protective anti-tumour T cell responses. In the CT26 BALB/c murine model of colorectal carcinoma, Tregs differentially suppress responses to two characterised CD8+ T epitopes, AH1 and GSW11, which results in an absence of detectable IFN-γ-producing GSW11-specific T cells in the spleen and lymph nodes of tumour challenged mice. Activation of GSW11-specific T cells correlates with protection against tumour progression. We wanted to examine the presence of non-functional GSW11-specific T cells in Treg replete and depleted mice, assess their phenotype and their affinity compared to AH1-specific T cells.

Methods

We used peptide-specific tetramers to identify tumour-specific CD8+ T cells and assessed the cell surface expression of markers associated with exhaustion (PD-1, Tim3 and Lag-3) and their function by IFN-g production using flow cytometry. We also assessed the T cell receptor (TcR) clonality of tumour-specific T cells. Tetramer competition assays were performed to determine the relative affinity of identified TcR.

Results

Here, we show that GSW11-specific T cells are in fact induced in Treg-replete, CT26-bearing mice, where they make up the majority of tumour-infiltrating CD8+ lymphocytes, but exhibit an ‘exhausted’ phenotype. This dysfunctional phenotype is induced early in the anti-tumour response in tumours. Depletion of Tregs prior to tumour challenge correlates with an altered T cell receptor (TcR) repertoire. Moreover, the avidity of GSW11-specific TcRs that expanded in the absence of Tregs was significantly lower compared with TcRs of CD8+populations that were diminished in protective anti-tumour responses.

Conclusion

Our results indicate that Tregs suppress the induction of protective anti-tumour T cell responses and may signify that low-avidity T cells play an important role in this protection.

Schlagwörter

Stichwörter der Autor:innen

antigen presentationimmunotherapyregulatory T celltumour immunity

Autor:innen und Institutionen

  • Centre for Cancer Immunology, School of Cancer Sciences, University of Southampton Faculty of Medicine, University Hospital Southampton, Southampton, UK.
  • Institute for Life sciences, University of Southampton, Southampton, UK.

ORCID-Profile: Edward James

Förderung

  • Cancer Research UK
  • Norman Godinho Foundation

Zitieren

APA

Sugiyarto, G., Prossor, D., Dadas, O., Arcia-Anaya, E. D., Elliott, T., & James, E. (2021). Protective low-avidity anti-tumour CD8+ T cells are selectively attenuated by regulatory T cells. Immunotherapy Advances. https://doi.org/10.1093/immadv/ltaa001

Vancouver

Sugiyarto G, Prossor D, Dadas O, Arcia-Anaya ED, Elliott T, James E. Protective low-avidity anti-tumour CD8+ T cells are selectively attenuated by regulatory T cells. Immunotherapy Advances. 2021. doi:10.1093/immadv/ltaa001

BibTeX
@article{Sugiyarto2021,
  author = {Sugiyarto, Gessa and Prossor, David and Dadas, Osman and Arcia-Anaya, E David and Elliott, Tim and James, Edward},
  title = {Protective low-avidity anti-tumour CD8+ T cells are selectively attenuated by regulatory T cells},
  journal = {Immunotherapy Advances},
  year = {2021},
  doi = {10.1093/immadv/ltaa001}
}
Kostenlos starten →